glp-1 agonists for type 2 diabetes Receptor as Treatments A clinician's perspective 📝 GLP-1

Others, such as Exubera (inhaled insulin) failed due to poor market penetration as well as safety concerns associated with drug accumulation in the lungs [217, 218]

Unlike endogenous GLP-1, liraglutide is stable against metabolic degradation by peptidases, with a plasma half-life of 13 hours

Among the RCTs, one study had some concerns due to the randomization process [20], while another exhibited some concerns in the intervention domain [30]

By virtue of their peptide character, the peptidomimetic inhibitors have poor pharmacokinetics due to susceptibility to metabolic cleavage by peptidases

In a clinical trial involving 112 patients, administration of the GLP-1 analogue exenatide led to a 21% faster reduction in blood lactate levels within 6 hours compared to placebo (95% CI: 6.0%33%